Everolimus: a challenging drug in the treatment of multifocal inoperable cardiac rhabdomyoma.
Pediatrics
; 130(1): e243-7, 2012 Jul.
Article
em En
| MEDLINE
| ID: mdl-22732179
ABSTRACT
Primary cardiac tumors are rare in childhood. The most common of these are rhabdomyomas. Considering that rhabdomyomas often show spontaneous regression, close follow-up may be sufficient in hemodynamically stable cases. However, hemodynamically significant cardiac rhabdomyomas confer a risk of morbidity and mortality. Herein, we report a newborn infant with multifocal cardiac rhabdomyomas treated with everolimus. The optimal dose of the drug was 0.25 mg 2 times per day, 2 days per week. Patients with inoperable cardiac rhabdomyomas and with symptoms may be candidates for everolimus treatment.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Rabdomioma
/
Sirolimo
/
Inibidores de Proteínas Quinases
/
Neoplasias Cardíacas
Tipo de estudo:
Diagnostic_studies
Limite:
Humans
/
Male
/
Newborn
Idioma:
En
Ano de publicação:
2012
Tipo de documento:
Article